Nanomedicine’s Next Frontier: Prof. Thomas J. Webster Headlines Cancer 2025

About the Keynote Speaker
With an h-index of 129 and more than 70 000 citations, Prof. Thomas J. Webster has spent three decades converting nanotechnology concepts into FDA-approved products—most notably nano-structured spinal implants now enhancing the lives of 30 000+ patients without a single recorded failure. The former president of the U.S. Society for Biomaterials, founder of a dozen med-tech start-ups (several acquired by Medtronic), and recent Nobel Prize nominee, Prof. Webster currently serves on the faculty at Brown University, Hebei University of Technology, and other institutions worldwide.


Keynote Preview
Anti-Cancer Nanomedicine in Humans: 30 000 Successful Cases and Counting

Prof. Webster will trace his journey from lab bench to operating room, revealing how nano-engineered surfaces outperform conventional implants—especially for bone-cancer patients, where failure rates can reach 60 %. Expect to learn:

  • How nano topographies destroy cancer cells, bacteria and inflammation without drugs

  • FDA MAUDE data validating zero failures across tens of thousands of patients

  • The emerging era of 4D-printed, environmentally friendly, AI-guided nano-materials poised to slash healthcare costs and extend global life expectancy


Why This Session Matters

Conventional Challenge Nano-enabled Solution Prof. Webster Will Showcase
5 – 10 % implant failure (up to 60 % in bone cancer) Nano spinal implants with a perfect clinical track record
Rising drug resistance & cost Drug-free cancer killing via nano surface physics
Reactive, one-size-fits-all healthcare Predictive sensors and smart nano-materials tailored to each patient

Event Snapshot

Secure Your Seat
Lock in an onsite pass or virtual ticket now → https://cancer.miconferences.com/register

Contact Us
✉ cancer@mathewsconference.com | ☎ +1 (312) 462-4448 | 💬 WhatsApp https://wa.me/14243770967

Join Prof. Webster and a global oncology community as we redefine cancer care through nanotechnology at Cancer 2025.

#Cancer2025 #Nanomedicine #Oncology #Biomaterials #NanoImplants #PrecisionMedicine #CPDCredits #CancerConferences #OncologyConferences #Anticancer

Sergey Suchkov’s Genomics Roadmap: Why Personalized & Precision Medicine Will Redefine Cancer Care at Cancer 2025

 


Speaker at a Glance
Prof. Sergey Suchkov, MD PhD, is a veteran clinical immunologist turned precision-health champion. Now Vice-Director for Research & Development at Mexico’s National Center for Human Photosynthesis, he also counts leadership stints at Russia’s MONIKI Institute and memberships in the New York Academy of Sciences, AHA, ACS, EPMA, and more. His four-decade career weaves together systems biology, immunology, and data-driven genomics to push healthcare from one-size-fits-all to truly individualized care.

Keynote Preview
“Personalized & Precision Medicine (PPM) Through Biodesign-Inspired Translational Research: Making Genomics Work for Oncologists, Caregivers & Patients.”

Prof. Suchkov will unpack how single-patient genomic signatures, next-generation sequencing, and biodesign-driven analytics can:
• Spot “biopredictors” of pre-cancer years before symptoms surface.
• Match actionable mutations to precisely targeted therapies.
• Balance biosafety, cost efficiency, and patient outcomes in real-world clinics.
• Integrate AI, bioengineering, and pathology into one seamless cancer-care continuum.

Why You Shouldn’t Miss It
– Learn a step-by-step framework for embedding genomics into routine oncology.
– Hear cost–benefit arguments that resonate with hospitals and payers.
– See case studies where early intervention prevented disease escalation.
– Network with researchers, biotech innovators, and policy shapers driving PPM adoption.

Conference Snapshot
• International Conference on Cancer Science & Research (Cancer 2025)
• Dates: 17–19 November 2025 | Hybrid format—Singapore venue + full virtual stream
• Earn CPD credits, publish in conference proceedings

Register & Connect
Early-bird pricing is live—secure your onsite seat or virtual pass today: https://cancer.miconferences.com/register 

Questions or partnership inquiries?
Email: cancer@mathewsconference.com | Phone: +1 (312) 462-4448 | WhatsApp: https://wa.me/14243770967

Join Prof. Suchkov and a global roster of oncology pioneers as we move from treating cancer after it strikes to predicting and preventing it before it gains ground.

#Cancer2025 #PrecisionMedicine #PersonalizedMedicine #Genomics #Biodesign #Oncology #CancerConference #SingaporeEvents #PredictiveHealthcare #CancerScienceConferences #OncologyEvents #OncologyEvents2025

Unmasking Ferroptosis Resistance in KRAS-Driven Lung Cancer: Prof. Ren-Wang Peng’s In-Person Talk at Cancer 2025

Speaker Profile
Prof. Ren-Wang Peng, Ph.D.—Associate Professor & Principal Investigator, University Hospital Bern (Inselspital) and Faculty of Medicine, University of Bern—has spent two decades decoding how solid tumours evade therapy. Trained at the Chinese Academy of Sciences, Max Planck Institute, and ETH Zürich, he leads an internationally collaborative lab focused on lung cancer, mesothelioma, cancer stem cells, and therapeutic resistance. His portfolio spans 100 + high-impact publications.



Talk Title
“Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer”

Why This Matters
Ferroptosis—an oxidative, iron-dependent form of cell death—should be a potent weapon against cancer, yet many tumours have learned to disarm it. Prof. Peng’s latest work reveals that the metabolic enzyme LDHB, not its better-known sibling LDHA, is a hidden shield that protects KRAS-mutant lung tumours from ferroptosis. Silencing LDHB crashes glutathione reserves, unleashing mitochondrial ROS and triggering a KRAS-specific synthetic lethality. The result: a new therapeutic window that pairs GSH-targeted agents with KRAS context for maximum tumour kill.

Key Takeaways for Attendees
• Distinguish LDHB from LDHA in ferroptosis defense
• Understand how STAT1-mediated repression of SLC7A11 dismantles glutathione metabolism
• Explore combination-therapy concepts that exploit ferroptosis susceptibility in KRAS-mutant lung cancer
• Gain translational insights ready for drug-development pipelines

Event Snapshot
• Conference: International Conference on Cancer Science & Research (Cancer 2025)
• Dates: 17 – 19 November 2025
• Format: Hybrid — Singapore & Global Online
• Theme: Oncology Nexus – Innovate, Collaborate, Conquer Cancer

Register & Participate
Secure your onsite seat or virtual pass to engage directly with Prof. Peng during live Q&A, network with peers across five precision-oncology tracks, and publish your research in proceedings.
👉 Register now: https://cancer.miconferences.com/register 

Contact
cancer@mathewsconference.com | +1 (312) 462-4448 | WhatsApp +1 (424) 377 0967


#Cancer2025 #Ferroptosis #KRAS #LungCancer #Oncology #CancerResearch #MetabolicTargets #SyntheticLethality #HybridConference #SingaporeEvents #CancerConference #CancerConference #SingaporeCancerConference #OncologyEvent

Hypoxia-Fibrosis Cycle in Pancreatic Cancer: Prof. Yan-Shen Shan’s Keynote at Cancer 2025

Speaker Spotlight
Prof. Yan-Shen Shan, M.D., Ph.D. — Dean, College of Medicine, National Cheng Kung University Hospital (NCKU), Taiwan; President-Elect of the Taiwan Surgical Society of Gastroenterology & Taiwan Gastric Cancer Society. With 260 + peer-reviewed papers and multiple national research awards, Prof. Shan is a leading voice in gastrointestinal oncology.

Keynote Session
“Hypoxia-Fibrosis Cycle in Pancreatic Cancer: Pathways Driving Tumor Progression & Predicting Poor Prognosis”

Discover how hypoxia-induced signaling and fibrosis feedback loops accelerate pancreatic ductal adenocarcinoma (PDAC), unveil novel biomarkers, and open doors to druggable targets.

Read the full abstract ➜
https://cancer.miconferences.com/program/scientific-program/2025/hypoxia-fibrosis-cycle-in-pancreatic-cancer-reveals-potential-pathways-associated-with-tumor-progression-and-predicts-poor-prognosis

Why Attend Cancer 2025?
• Unpack translational data that links tumor micro-environment dynamics to real-world outcomes.
• Gain insights that sharpen prognosis and personalize therapy for PDAC patients.
• Engage live with Prof. Shan during an interactive Q&A session.

Event Snapshot
• Conference: International Conference on Cancer Science & Research (Cancer 2025)
• Dates: 17 – 19 November 2025
• Format: Singapore 🇸🇬 (in-person) & Global Online 🌐

Secure Your Seat
Early-bird pricing ends soon—reserve your spot today:
➡️ https://cancer.miconferences.com/register

Join the Conversation
• Twitter: https://x.com/CancerWorldConf
•  Email: cancer@mathewsconference.com
•  Whatsapp: +1 (424) 377 0967




#PancreaticCancer #GIOncology #Oncology #CancerResearch #Hypoxia #Fibrosis #PrecisionMedicine #CancerConference #Cancer2025 #SingaporeEvents #GastrointestinalCancer #MedicalInnovation #TranslationalResearch #TumorMicroenvironment

Don’t miss this milestone session at Cancer 2025. Learn from a global leader, connect with peers, and help shape the future of precision oncology.

Unlocking Precision Oncology: Live Keynote by Dr. Rajvir Dahiya at Cancer 2025

Why This Session Matters

Precision medicine is transforming how we diagnose, monitor, and treat cancer. At Cancer 2025, you’ll have a rare opportunity to hear Dr. Rajvir Dahiya—University of California San Francisco School of Medicine, USA—present in person on “A Novel mRNA Genomic Technology for Precision Medicine, Cancer Diagnosis, Prognosis & Treatment Follow-Up.”

What You’ll Learn
• How cutting-edge mRNA genomic profiling pinpoints actionable mutations in real time
• New algorithms that predict patient prognosis and guide therapy selection
• Case studies demonstrating improved survival and reduced recurrence rates
• Practical steps to integrate genomic data into clinical workflows

About Dr. Rajvir Dahiya
Dr. Rajvir Dahiya—PhD (PGIMER India), MD (Kagoshima Univ., Japan), DSc (Osaka Univ., Japan)—is a globally acclaimed molecular oncologist and founding Director of the Urology Oncology Research Center at UCSF/VA Medical Center, where he served for 34 years before becoming Professor Emeritus. He has authored 550+ peer-reviewed papers, earned 35,500+ citations with a D-index of 107, and led 99 NIH and VA-funded projects that advanced mRNA-based diagnostics and precision oncology, resulting in multiple patents.

Event Snapshot
• Conference: International Conference on Cancer Science & Research (Cancer 2025)
• Date: 17-19, November 2025
• Location: Singapore and Online

Secure Your Seat
Spaces for this high-impact session are limited. Register now to guarantee your spot and gain full conference access: https://cancer.miconferences.com/register

Join the Conversation:
• Twitter: https://x.com/CancerWorldConf
• Email: cancer@mathewsconference.com
• Whatsapp: +1 (424) 377 0967



#Oncology #mRNA #CancerResearch #PrecisionMedicine #CancerConference #Cancer2025 #GenomicTechnology #UCSF #SingaporeEvents

Don’t miss this chance to witness a breakthrough in precision oncology, learn directly from a global leader, and connect with peers shaping the future of cancer care. We look forward to welcoming you to Cancer 2025!

Announcing Cancer 2025 – International Conference on Cancer Science & Research

Mark your calendar: 17 – 19 November 2025, Singapore and Online. Cancer 2025 will unite scientists, clinicians, industry pioneers, patient advocates, and policy-makers in a hybrid forum dedicated to accelerating progress against cancer.

Reasons to attend

  • All-embracing scientific agenda – sessions on genomics, ultra-early detection, AI-powered diagnostics, precision oncology, survivorship, drug & vaccine discovery and more.

  • Renowned keynote speakers – hear cutting-edge insights from global oncology leaders reshaping clinical standards.

  • Seamless hybrid networking – poster halls, 1-to-1 partnering, and live Q&A—onsite or via our virtual platform.

  • Strategic forums – regulators, pharma and biotech share perspectives on moving breakthroughs from lab bench to bedside.

Join the conversation

From tumour-biology breakthroughs to first-in-human trials, Cancer 2025 is the place to collaborate, learn, and drive oncology innovation forward.

“Together, today’s breakthroughs can become tomorrow’s cures.” – Organising Committee

We look forward to welcoming you in Singapore—or online—this November.

#Cancer2025 #CancerConference #OncologyConference #CancerScience #CancerResearch #CancerInnovation #SingaporeEvents #HybridConference

Subscribe to: Posts (Atom)